The Food and Drug Administration (FDA) has approved eye drops containing NGF, which hold promise in the treatment of neurotrophic keratitis and may prove to be an effective treatment in other ophthalmic conditions requiring corneal regeneration, such as keratoconus [26,27]. The gene discussed is NGF; the disease is keratoconus.